Table 2.
Subgroup analysis of the prognostic value of HB.
| Survival analysis | No. of studies | I2 (%) | HR (95%CI) | P |
| OS | ||||
| Total | 9 | 75.9% | 2.13 (1.52–2.98) | P < .00001 |
| Treatment | ||||
| Surgery | 3 | 88% | 1.72 (1.08–2.73) | P = .02 |
| Mixed | 3 | 0% | 2.15 (1.46–3.16) | P < .0001 |
| Drug | 2 | 59% | 3.29 (1.37–7.92) | P = .008 |
| Stage | ||||
| Nonmetastatic | 1 | 7% | 2.63 (1.89–3.67) | P < .00001 |
| Metastatic | 3 | 38% | 2.56 (1.61–4.06) | P < .0001 |
| Mixed | 4 | 0% | 2.11 (1.52–2.92) P < .00001 I2 = 0% | P < .00001 |
| Ethnicity | ||||
| Asian | 1 | 0% | 2.02 (1.35–3.01) | P = .0006 |
| Caucasian | 7 | 81% | 2.16 (1.48–3.16) | P < .0001 |
| DSS | ||||
| Total | 6 | 61% | 1.53 (1.20–1.96) | P = .02 |
| Treatment | ||||
| Surgery | 4 | 52% | 1.55 (1.20–1.99) | P = .0006 |
| Mixed | 2 | 84% | 1.52 (0.65–3.54) | P = .33 |
| Stage | ||||
| Nonmetastatic | 3 | 0% | 2.23 (1.63–3.06) | P < .00001 |
| Metastatic | 1 | NA | 1.01 (0.69–1.48) | P = .95 |
| Mixed | 2 | 44% | 1.35 (1.08–1.70) | P = .008 |
| Ethnicity | ||||
| Asian | 1 | NA | 1.01 (0.69–1.48) | P = 0.95 |
| Caucasian | 5 | 56% | 1.52 (1.32–1.76) | P < .00001 |
| DFS | ||||
| Total | 4 | 60% | 1.55 (1.10–2.17) | P = .01 |
| Treatment | ||||
| Surgery | 1 | NA | 1.19 (1.03–1.37) | P = .02 |
| Mixed | 1 | NA | 1.52 (0.90–2.56) | P = .12 |
| Drug | 2 | 27% | 2.01 (1.34–3.01) | P = .0008 |
| Stage | ||||
| Metastatic | 3 | 2% | 1.81 (1.31–2.49) | P = .0003 |
| Mixed | 1 | NA | 1.19 (1.03–1.37) | P = .02 |
| Ethnicity | ||||
| Asian | 1 | NA | 1.52 (0.90–2.56) | P = .12 |
| Caucasian | 3 | 72% | 1.62 (1.02–2.59) | P = .04 |
DFS = disease-free survival, DSS = disease-specific survival, OS = overall survival.